3 results
To compare tisagenlecleucel treatment strategy to SOC treatment strategy with respect to delaying the composite event of disease progression / stable disease at or after the week 12 assessment; or death at any time.
The primary objective of this study is to evaluate the efficacy of psilocybin (25 mg or 10 mg) compared to 1 mg, administered under supportive conditions to adult participants with TRD, in improving depressive symptoms, as assessed by the change in…
This single arm, multi-center, phase II study will determine the efficacy and safety of tisagenlecleucel in adult patients with FL who failed at least 2 prior systemic therapies, including an anti-CD20 antibody (e.g. rituximab) and an alkylating…